September 26, 2016 3:41 AM ET

Biotechnology

Company Overview of Precision BioSciences, Inc.

Company Overview

Precision BioSciences, Inc., a biotechnology company, engages in developing and commercializing therapeutics and services based on genomic molecular biology. It offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock. The company was founded in 2006 and is based in Research Triangle Park, North Carolina.

302 East Pettigrew Street

Dibrell Building Suite A-100

Durham, NC 27701

United States

Founded in 2006

Phone:

919-314-5512

Fax:

480-393-5553

Key Executives for Precision BioSciences, Inc.

Co-Founder, Chief Executive Officer and Director
Chief Operations Officer and Chief Financial Officer
Senior Vice President of Gene Therapy
Senior Vice President of Cell Therapy
Age: 57
Director of Cell Biology
Compensation as of Fiscal Year 2016.

Precision BioSciences, Inc. Key Developments

Precision BioSciences, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 02:35 PM

Precision BioSciences, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-13-2016 02:35 PM. Venue: Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Mike Dombeck.

Baxalta Enters into a Global Collaboration with Precision Biosciences

Baxalta has announced that it has entered into a global collaboration with Precision Biosciences (US) to develop a broad series of allogeneic chimeric antigen receptor (CAR) T-cell therapies directed towards multiple cancers. Under the terms of the deal, the two companies will develop CAR T therapies for up to six unique targets, with the first programme expected to enter clinical studies in late 2017. Precision will conduct early-stage research activities up to Phase II, after which Baxalta has exclusive rights to late-stage development and commercialisation. Precision will receive an upfront payment of USD 105 million from Baxalta, with additional option fees and milestones potentially totaling up to USD 1.6 billion, in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialisation of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. The collaboration will make use of Precision BioSciences' proprietary ARCUS genome editing technology, which enables the production of CAR T cells derived from healthy donors rather than relying on the patient. This approach aims to overcome the manufacturing limitations of existing CAR T therapies and enable the targeting of a broader range of malignancies.

Baxalta Incorporated and Precision Biosciences Announces Global Collaboration to Develop Broad Series of Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapies

Baxalta Incorporated and Precision BioSciences announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. CAR T is widely recognized as a breakthrough technology with the potential to become a curative option for certain malignancies. Most CAR T cell therapy technologies isolate cells from cancer patients’ blood and re-engineer them to specifically target receptors on tumor cells. The reprogrammed cells are multiplied in a laboratory and then returned to the patient to target the tumor. This approach has had initial success in clinical trials for certain tumor types, but persistent scaling challenges remain based on the highly personalized nature of the therapy. Precision BioSciences’ proprietary ARCUS genome editing technology enables the production of CAR T cells derived from healthy donors rather than relying on the patient. This approach aims to overcome the manufacturing-related limitations with existing CAR T therapies and enable a broader range of malignancies to be targeted. Under the terms of the agreement, Baxalta and Precision BioSciences will develop CAR T therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017. Precision BioSciences will be responsible for performing early-stage research activities up to Phase 2, following which Baxalta has the exclusive right to opt in for late-stage development and commercialization. Precision BioSciences will receive an upfront payment of $105 million from Baxalta, with additional option fees, developmental, clinical, regulatory, and sales milestones, potentially totaling up to $1.6 billion, in addition to royalties on worldwide sales. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. Additional terms and initial targets were not disclosed. The agreement follows another recently established Baxalta collaboration to advance novel therapeutics against checkpoint targets, advancing the company’s strategic commitment to investing in immuno-oncology and building an innovative portfolio of cancer immunotherapies.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Precision BioSciences, Inc., please visit www.precisionbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.